Zentiva, a pharmaceutical company, completed the acquisition of Creo Pharmaceuticals, a pharmaceutical company providing generics, commercial brands and specialist supply products, from Amneal Pharmaceuticals, a pharmaceutical company. Financial terms were not disclosed. "Zentiva is delighted to confirm the acquisition of Creo Pharma which will strengthen Zentiva’s position in the UK. This move reflects our confidence in the UK and our deep commitment to the development, manufacture and supply of high-quality affordable medicines. We welcome the Creo Pharma team who have a strong reputation for providing high-quality services to their customers," Nick Haggar, Zentiva CEO.